A Califf Regime: The Disruptor FDA, Industry Needs
This article was originally published in Scrip
Executive Summary
If Robert Califf is confirmed as the next commissioner of the FDA – which most in the biopharmaceutical community are anticipating is all but assured – he'll be taking over an agency that's in the midst of some of the most complicated challenges it's ever faced, the resolutions of which have broad implications for drug and device makers.